You are here

Article info

Article menu

Download PDFPDF

XML
Recent advances in basic science
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine

Authors

  • James RW Conway Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • David Herrmann Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • TR Jeffry Evans Cancer Department, Cancer Research UK Beatson Institute, Glasgow, UK Institute of Cancer Sciences, University of Glasgow, Glasgow, UK PubMed articlesGoogle scholar articles
  • Jennifer P Morton Cancer Department, Cancer Research UK Beatson Institute, Glasgow, UK Institute of Cancer Sciences, University of Glasgow, Glasgow, UK PubMed articlesGoogle scholar articles
  • Paul Timpson Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Paul Timpson, Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia; p.timpson{at}garvan.org.au
View Full Text

Citation

Conway JR, Herrmann D, Evans TJ, et al
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Gut 2019;68:742-758.

Publication history

  • Received June 12, 2018
  • Revised October 2, 2018
  • Accepted October 4, 2018
  • First published November 5, 2018.
Online issue publication 
March 07, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.